Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews ; volume:18 ; number:1 ; day:3 ; month:9 ; year:2018 ; pages:1-13 ; date:12.2018
BMC psychiatry ; 18, Heft 1 (3.9.2018), 1-13, 12.2018
- Urheber
-
Ijaz, Sharea
- Beteiligte Personen und Organisationen
-
Bolea, Blanca
Davies, Simon
Savović, Jelena
Richards, Alison
Sullivan, Sarah
Moran, Paul
SpringerLink (Online service)
- DOI
-
10.1186/s12888-018-1848-y
- URN
-
urn:nbn:de:101:1-2018103122124367913117
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ijaz, Sharea
- Bolea, Blanca
- Davies, Simon
- Savović, Jelena
- Richards, Alison
- Sullivan, Sarah
- Moran, Paul
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Antipsychotic polypharmacy prescribing and risk of hospital readmission
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan
Antipsychotic polypharmacy in a regional health service: a population-based study
Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
Polypharmacy in schizophrenia - therapeutic option or a sign of despair?
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Antipsychotic polypharmacy prescribing and risk of hospital readmission
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan
Antipsychotic polypharmacy in a regional health service: a population-based study
Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
Polypharmacy in schizophrenia - therapeutic option or a sign of despair?
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Antipsychotic polypharmacy prescribing and risk of hospital readmission
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan
Antipsychotic polypharmacy in a regional health service: a population-based study
Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms
Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process